KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Revenue (2023 - 2025)

Biocryst Pharmaceuticals' Revenue history spans 9 years, with the latest figure at $708000.0 for Q4 2025.

  • For Q4 2025, Revenue fell 99.46% year-over-year to $708000.0; the TTM value through Dec 2025 reached $469.0 million, up 4.06%, while the annual FY2025 figure was $874.8 million, 94.1% up from the prior year.
  • Revenue reached $708000.0 in Q4 2025 per BCRX's latest filing, down from $159.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $325.2 million in Q4 2023 to a low of $708000.0 in Q4 2025.
  • Average Revenue over 3 years is $138.3 million, with a median of $131.5 million recorded in 2024.
  • The largest YoY upside for Revenue was 56.89% in 2025 against a maximum downside of 99.46% in 2025.
  • A 3-year view of Revenue shows it stood at $325.2 million in 2023, then crashed by 59.55% to $131.5 million in 2024, then plummeted by 99.46% to $708000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Revenue are $708000.0 (Q4 2025), $159.4 million (Q3 2025), and $163.4 million (Q2 2025).